Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mojgan Khatami

Gynecology Kennesaw, GA Medical Doctor

NPI 1770555070 CMS profile 125458

1690 Stone Village Ln Nw, Suite401, Kennesaw, GA 30152

Open in the dashboard

General payments

$2,026

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mojgan Khatami of Kennesaw, GA is reported in the CMS Open Payments database as having received $2,026 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $87 8
2024 General $134 16
2023 General $238 19
2022 General $272 23
2021 General $672 36
2020 General $387 23
2019 General $235 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mojgan Khatami
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Mojgan Khatami were reported at $87. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Mojgan Khatami Gynecology median Middle half National median
2019 $235 $199 $66–$472 $163
2020 $387 $114 $42–$287 $114
2021 $672 $141 $42–$430 $132
2022 $272 $173 $52–$532 $149
2023 $238 $170 $57–$501 $160
2024 $134 $157 $50–$424 $164
2025 $87 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $700 40 payments
  2. Mayne Pharma Inc. $488 48 payments
  3. Evofem Biosciences, Inc. $208 14 payments
  4. Millicent US Inc $114 6 payments
  5. TherapeuticsMD, Inc. $88 5 payments
  6. Astellas Pharma US Inc $75 6 payments
  7. Organon LLC $71 5 payments
  8. Exeltis, USA Inc. $66 4 payments
  9. Agile Therapeutics, Inc. $42 2 payments
  10. ASCEND Therapeutics US, LLC $32 2 payments
  11. Other $142 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,001 138 payments
  2. Education $24 2 payments
Products named General payments · program years 2019–2025
  1. ORILISSA Womens Health $266 11 payments
  2. ORIAHNN $248 10 payments
  3. LO LOESTRIN FE $174 12 payments
  4. Phexxi Miscellaneous vaginal agent $151 8 payments
  5. SYNTHROID $117 7 payments
  6. FEMRING $114 6 payments
  7. Orilissa Endocrinology $92 6 payments
  8. MYRBETRIQ $75 6 payments
  9. NEXPLANON $59 4 payments
  10. Phexxi Contraceptives $57 6 payments
  11. Other $520 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

52

Median for Obstetrics & Gynecology: 65

Drug cost

$3,756

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

65.4%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imvexxy Estradiol Brand 12 $2,544
Estradiol Generic 18 $465
Estradiol (Twice Weekly) Estradiol Brand 11 $455
Progesterone Progesterone, Micronized Brand 11 $292

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$3,017

Medicare's payments for the services billed

Medicare patients

23

Average age 70

Services billed

69

23 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ESTROGEL
  • ASCEND Therapeutics US, LLC $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record